İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - rubellavirus mumps vaccine (live attenuated) -

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - recombinant vesicular stomatitis virus (strain indiana) with a deletion of the envelope glycoprotein, replaced with the zaire ebolavirus (strain kikwit 1995) surface glycoprotein - hemorrhagic fever, ebola - vaccines - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus.the use of ervebo should be in accordance with official recommendations.

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemorrhagic fever, ebola - vaccines - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.,

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hemorrhagic fever, ebola - vaccines - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.,

Kanada - İngilizce - Health Canada

merck canada inc - ebola zaÏre vaccine (rvsv [delta] g-zebov-gp, live) - solution - 72000000pfu - ebola zaÏre vaccine (rvsv [delta] g-zebov-gp, live) 72000000pfu

ABD - İngilizce - NLM (National Library of Medicine)

merck sharp & dohme llc - zaire ebolavirus (strain kikwit-95) envelope glycoprotein (unii: xh5v2sq5fi) (zaire ebolavirus (strain kikwit-95) envelope glycoprotein - unii:xh5v2sq5fi) - ervebo® is indicated for the prevention of disease caused by zaire ebolavirus in individuals 12 months of age and older. - the duration of protection conferred by ervebo is unknown. - ervebo does not protect against other species of ebolavirus or marburgvirus . - effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (ig), and/or blood or plasma transfusions is unknown. do not administer ervebo to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including rice protein [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. there are no adequate and well-controlled studies of ervebo in pregnant women, and human data available from clinical trials with ervebo are ins

Uganda - İngilizce - National Drug Authority

janssen-cilag international nv - one dose (0.5 ml) contains:modified vaccinia ankara bavarian nordic virus* encoding the: zaire ebolavirus (ebov) mayinga variant glycoprotein (gp), sudan ebolavirus gulu variant gp, taÏ forest ebolavirus nucleoprotein, marburg marburgvirus musoke variant - parenteral ordinary vials - not less than 0.7 x 108 infectious units (inf.u), /dose (0.5 ml)

Uganda - İngilizce - National Drug Authority

janssen-cilag international nv - adenovirus type 26 encoding the zaire ebolavirus (ebov) mayinga variant glycoprotein (gp), - parenteral ordinary vials - not less than 8.75 log 10 infectious units (inf.u),/dose (0.5 ml)

Malta - İngilizce - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - clobetasol propionate - cutaneous liquid - clobetasol propionate 0.05 % (w/w) - corticosteroids, dermatological preparations

Kanada - İngilizce - Health Canada

fresenius kabi canada ltd - adalimumab - solution - 40mg - adalimumab 40mg - disease-modifying antirheumatic agents